EXCLUSIVE: BioRestorative Poised To Receive European Patent For ThermoStem Program

The European Patent Office has issued a notice of allowance for a patent application related to BioRestorative Therapies Inc's BRTX metabolic ThermoStem program. 

The notice of allowance was issued on February 6, 2023.

What Happened: Claims granted under the new patent cover implantable three-dimensional scaffolds and brown adipocytes derived from human brown adipose-derived stem cells. 

Related: EXCLUSIVE: BioRestorative Secures Funding Support For Programs Against Polycystic Ovary Syndrome.

The therapeutic combination of scaffolds as a delivery system and brown adipose-derived stem cells provides the ability to deliver metabolically active cells. 

Why It Matters: The therapeutic benefits of using brown adipose have been demonstrated in various models. Certain companies that use encapsulation technology coupled with cells have shown promising clinical results in treating type 1 diabetes in their Phase 1/2 clinical trials.

"We are committed to the development of ThermoStem as a potential treatment for obesity and metabolic disorders, such as type 2 diabetes," said Lance Alstodt, the company's CEO. 

Price Action: BRTX shares are up 2.31% at $3.08 premarket on the last check Wednesday.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMarket-Moving ExclusivesExclusivesGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!